Tumor Progression
Tumor progression remains a leading cause of cancer-related mortality worldwide, driven by the aggressive growth and spread of cancer cells to distant organs. This progression is often fueled by molecular changes within cancer stem cells (CSCs) and signaling pathways that promote metastasis and invasion.
The Role of ALDH1A3 in Tumor Progression
ALDH1A3 plays a central role in the processes that drive tumor progression:
- Metastasis: ALDH1A3 enhances the ability of cancer cells to invade surrounding tissues and establish secondary tumors in distant organs.
- Cancer Stem Cell Plasticity: It regulates the balance of cancer stem cell populations, driving epithelial-to-mesenchymal transition (EMT), which is crucial for metastasis.
- Metabolic Shifts: ALDH1A3 alters glycometabolism, providing cancer cells with the energy needed for rapid growth and invasion.
How Theranib Addresses This Challenge
Theranib Inc.’s groundbreaking therapy, VE3, is designed to combat tumor progression by targeting ALDH1A3 and disrupting its tumor-promoting effects:
- Inhibiting Metastasis: VE3 reduces the ability of ALDH1A3-expressing cells to migrate and invade, limiting the spread of cancer to other organs.
- Targeting Cancer Stem Cells: By suppressing ALDH1A3 activity, VE3 disrupts the survival and plasticity of cancer stem cells, which are key drivers of tumor progression.
- Restoring Balance: VE3 reverses the metabolic and signaling changes induced by ALDH1A3, reducing the aggressive behavior of tumor cells.
The Impact
By addressing the underlying drivers of tumor progression, Theranib’s approach not only slows cancer growth but also reduces the likelihood of metastasis. This innovative solution represents a critical advancement in improving survival rates and quality of life for patients with aggressive cancers.